SAN DIEGO, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the following three investor conferences, each of which will be webcast live and for replay at http://www.apricusbio.com/investor-relations/presentations/.
| SeeThruEquity Microcap Investor Conference |
| Wednesday, November 12, 2014 |
| Presentation at 9:30 a.m. ET |
| Convene Midtown East, New York, NY |
| Online Registration |
| Stifel 2014 Healthcare Conference |
| Tuesday, November 18, 2014 |
| Presentation at 4:45 p.m. ET |
| The New York Palace Hotel, New York, NY |
| LD Micro Conference |
| Thursday, December 4, 2014 |
| Presentation at 11:00 a.m. PT |
| Luxe Hotel, Los Angeles, CA |
Management will review its plans for growth to include discussing its robust pipeline of marketed and development stage products:
- Vitaros®, the Company's topical treatment for erectile dysfunction which launched in Belgium this week and in the United Kingdom, Germany and Sweden earlier this year;
- Fispemifene, Apricus' newly in-licensed drug candidate for male urological conditions including low testosterone "Low T" also known as secondary hypogonadism, is slated for a phase 2b trial to commence in the first half of 2015;
- RayVa™, a potential first-in-class drug candidate for the circulatory disorder, Raynaud's phenomenon, which will commence a ~50 patient phase 2a proof of concept trial in Q4 of this year.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines to meet the needs of patients. The Company's lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and commercialized in several countries in Europe. Apricus' marketing partners for Vitaros® include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. The Company recently initiated a Phase 2a trial for RayVa™, the Company's product candidate for the treatment of Raynaud's phenomenon. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox. In October 2014, Apricus gained U.S. development and commercialization rights for fispemifene, a selective estrogen receptor modulator, in Phase 2 development.
For further information on Apricus, visit http://www.apricusbio.com.